AstraZeneca Pharma India Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on AstraZeneca Pharma India Ltd. from all sources in a single place.

Load latest

AstraZeneca Pharma India Ltd.

01 May 2024, 09:14AM

9336.50

17.12%

'Sympathy goes out to anyone who lost loved ones,' says AstraZeneca on Covishield row

Business Today

The admission came a day after the pharma giant admitted in a UK court that its COVID-19 vaccine sold globally as Covishield and Vaxzevria may cause Thrombocytopenia Syndrome (TTS) in "very rare cases".

AstraZeneca Pharma India Ltd. has gained 42.23% in the last 6 Months

Vaccination benefits outweigh risks of extremely rare potential side effects, says AstraZeneca, citing regulators

Business Line | 30 Apr 2024 3 more

AstraZeneca Pharma India Ltd.

19 Apr 2024

9336.50

17.12%

Corp. Note

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Format of the Initial Disclosure to be made by …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyASTRAZENECA PHARMA INDIA LTD. 2CIN NO.L24231KA1979PLC003563 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY 000 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Manasa R Designation: Company Secretary EmailId: manasa.r1@astrazeneca.com Name of the Chief Financial Officer: Bhavana Agrawal Designation: Chief Financial Officer and Director EmailId: bhavana.agrawal@astrazeneca.com Date: 19/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

AstraZeneca Pharma India Ltd.

16 Apr 2024

9336.50

17.12%

Company Update

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Certificate Under Regulation 40(10) Of SEBI (Listing Obligations And …

BSE India

As required under Regulation 49(10) of SEBI (LODR) Regulations, 2015, we furnish herewith a certificate issued by the Practising Company Secretary with regard to transfer of securities effected during the year ended March 31, 2024.

pdf

AstraZeneca Pharma India Ltd.

12 Apr 2024

9336.50

17.12%

Company Update

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And …

BSE India

This is to certify that Integrated Registry Management Services Private Limited, are the Company''s RTA and that all activities are in relation to the share transfer are maintained by them. We are also attaching the certificate received from our RTA.

pdf

AstraZeneca Pharma India Ltd.

12 Apr 2024

9336.50

17.12%

Company Update

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, …

BSE India

We are enclosing herewith the Certificate dated April 5, 2024 issued by the RTA of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.

pdf

AstraZeneca Pharma India Ltd.

08 Apr 2024

9336.50

17.12%

AGM

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Shareholder Meeting / Postal Ballot-Outcome of Postal Ballot

BSE India

This is in reference to our letter dated March 6, 2024, enclosing therewith a Postal Ballot Notice dated February 8, 2024 seeking consent of the members of the Company through Special Resolution for appointment of Ms. Bhavana Agrawal (DIN: 10485441) as a Director and also as a Whole-time Director of the Company. In relation to the same, we are enclosing herewith the Voting results along with the Scrutinizer''s Report and the same are being placed on the Company''s website and website of National Securities Depository Limited.

pdf

AstraZeneca Pharma India Ltd.

08 Apr 2024

9336.50

17.12%

AstraZeneca, Daiichi drug gets broad tumor approval in US

Moneycontrol

The US Food and Drug Administration cleared the medicine for patients who have HER2-positive solid tumors that have spread or can't be removed with surgery, the company said. These patients have already received prior treatment and don't have any good alternatives.

AstraZeneca Pharma India Ltd. has gained 51.09% in the last 1 Year

AstraZeneca Pharma India Ltd.

08 Apr 2024

9336.50

17.12%

Company Update

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Summary Of Proceedings Of 44Th Annual General Meeting

BSE India

In furtherance to your email dated April 6, 2024 and the enclosed summary of proceedings of 44th Annual General Meeting held on August 14, 2023, we wish to inform that that the 44th Annual General Meeting commenced at 3:00 PM and concluded at 4:45 PM (IST).

pdf

AstraZeneca Pharma India Ltd.

05 Apr 2024

9336.50

17.12%

AstraZeneca Says Key Lung Cancer Drug Improved Survival

NDTV Profit

Lung cancer is the leading cause of cancer death among men and women, accounting for about 20% of all cancer deaths.

Number of FII/FPI investors increased from 147 to 164 in Mar 2025 qtr.

AstraZeneca Pharma India Ltd.

26 Mar 2024

9336.50

17.12%

Company Update

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015

BSE India

This is to inform that AstraZeneca Pharma India Limited has received permission to import for sale and distribution of Trastuzumab deruxtecan lyophilized powder for concentrate for solution for infusion 100mg (Enhertu) from Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India for the attached additional indications.

pdf

Is AstraZeneca Pharma India Ltd. worth buying?

146 Votes:

Buy 70.55%

Sell 19.86%

Hold 9.59%

New 52W High today

High volume+gain today

AstraZeneca Pharma India Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on AstraZeneca Pharma India Ltd. from all sources in a single place.